Clinical Trial Detail

NCT ID NCT01871311
Title A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Georgetown University
Indications

colorectal cancer

head and neck squamous cell carcinoma

Therapies

Cetuximab + Nilotinib

Age Groups: adult

No variant requirements are available.